Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma

Fu, Hangcheng; Liu, Yidong; Xu, Lingxia; Chang, Yuan; Zhou, Lin; Zhang, Weijuan; Yang, Yuanfeng; Xu, Jiejie

doi:10.1097/md.0000000000003225

Cited by 15 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown that EPB41L3 gene expression is altered in RCC . In addition, MUC4 was previously shown to be aberrantly expressed in ccRCC . Consistent with the present findings, Niu et al .…”

Section: Discussionsupporting

confidence: 92%

“…36,37 In addition, MUC4 was previously shown to be aberrantly expressed in ccRCC. 38,39 Consistent with the present findings, Niu et al found that RAP1B mRNA levels are elevated in ccRCC tissues relative to adjacent normal renal tissues. 40 Additionally, Wang et al showed that the RAP1B expression was significantly elevated in RCC tumors compared to nontumorous tissues.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Searching for prognostic biomarkers for small renal masses in the urinary proteome

Meo

Batruch

Brown

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is frequently diagnosed incidentally as an early‐stage small renal mass (SRM; pT1a, ≤4 cm). Overtreatment of patients with benign or clinically indolent SRMs is increasingly common and has resulted in a recent shift in treatment recommendations. There are currently no available biomarkers that can accurately predict clinical behavior. Therefore, we set out to identify early biomarkers of RCC progression. We employed a quantitative label‐free liquid chromatography coupled to tandem mass spectrometry (LC‐MS/MS) proteomics approach and targeted parallel‐reaction monitoring to identify and validate early, noninvasive urinary biomarkers for RCC‐SRMs. In total, we evaluated 115 urine samples, including 33 renal oncocytoma (≤4 cm) cases, 30 progressive and 26 nonprogressive clear cell RCC (ccRCC)‐SRM cases, in addition to 26 healthy controls. We identified six proteins, which displayed significantly elevated expression in clear cell RCC‐SRMs (ccRCC‐SRMs) relative to healthy controls. Proteins C12ORF49 and EHD4 showed significantly elevated expression in ccRCC‐SRMs compared to renal oncocytoma (≤4 cm). Additionally, proteins EPS8L2, CHMP2A, PDCD6IP, CNDP2 and CEACAM1 displayed significantly elevated expression in progressive relative to nonprogressive ccRCC‐SRMs. A two‐protein signature (EPS8L2 and CCT6A) showed significant discriminatory ability (areas under the curve: 0.81, 95% CI: 0.70–0.93) in distinguishing progressive from nonprogressive ccRCC‐SRMs. Patients (Stage I–IV) with EPS8L2 and CCT6A mRNA alterations showed significantly shorter overall survival (p = 1.407 × 10−6) compared to patients with no alterations. Our in‐depth proteomic analysis identified novel biomarkers for early‐stage RCC‐SRMs. Pretreatment characterization of urinary proteins may provide insight into early RCC progression and could potentially help assign patients to appropriate management strategies.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

Searching for prognostic biomarkers for small renal masses in the urinary proteome

Meo

Batruch

Brown

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…In recent years, there has been a growing interest in identifying novel tumor markers not only for diagnostic purposes but also to improve the prediction of prognosis 3,4. Combining the molecular biomarkers with conventional models might provide more individualized diagnosis and treatment based on molecular characteristics of the tumor 5–7…”

Section: Introductionmentioning

confidence: 99%

High expression of Aldolase A predicts poor survival in patients with clear-cell renal cell carcinoma

Na¹,

Li²,

Xu³

et al. 2017

TCRM

View full text Add to dashboard Cite

BackgroundAldolase A (ALDOA) is a glycolytic enzyme that drives the glycolytic metabolic pathway in mammalian cells. The overexpression of ALDOA was observed in a variety of cancers including clear-cell renal cell carcinoma (ccRCC). However, little was known about the clinicopathological significance and prognostic value of ALDOA in ccRCC patients.MethodsThe expression of ALDOA was detected using immunohistochemical staining in 162 formalin-fixed, paraffin-embedded ccRCC sections. Prognostic outcomes correlated with ALDOA were examined using Kaplan–Meier analysis and the Cox proportional hazards model.ResultsIn patients with ccRCC, increased cytoplasmic ALDOA expression was positively associated with tumor size (P=0.021), TNM stages (P=0.034), lymph node metastasis (P=0.020), and overall survival (OS) (P<0.001). Kaplan–Meier analysis showed that high cytoplasmic expression of ALDOA was associated with a statistically significant lower OS (P<0.001). Multivariate analysis demonstrated that ALDOA expression was an independent and significant prognostic factor (HR =3.561, 95% CI =1.715–7.396, P=0.001). ALDOA expression was not associated with significant prognostic deference in the subgroups of TNM stage I patients or pT1 patients.ConclusionOur results suggest that ALDOA expression is an independent prognostic factor for OS in patients with ccRCC.

show abstract

“…However, sometimes discrepancies arise between predictions and practical clinical outcomes 4. Recent studies have revealed a number of prognostic biomarkers that are associated with different features of RCC biology, and novel models that combine conventional clinicopathological factors with molecular biomarkers have been established to allow for more a precise prediction of clinical outcomes 5–8. Therefore, it is of great value to seek molecular markers that will improve the individual therapeutic management and clinical outcome of patients with ccRCC.…”

Section: Introductionmentioning

confidence: 99%

High expression of HMGA2 predicts poor survival in patients with clear cell renal cell carcinoma

Na¹,

Si²,

Huang³

et al. 2016

OTT

View full text Add to dashboard Cite

High-mobility group AT-hook 2 (HMGA2) is involved in a wide spectrum of biological processes and is upregulated in several tumors, but its role in renal carcinoma remains unclear. The aim of this study was to examine the expression of HMGA2 and its relationship to the overall survival (OS) of patients with non-metastatic clear cell renal cell carcinoma (ccRCC) following surgery. The expression of HMGA2 was evaluated retrospectively by immunohistochemistry (IHC) in 162 patients with ccRCC who underwent nephrectomy in 2003 and 2004. An IHC analysis revealed that HMGA2 was expressed in the nuclei of tumor cells in 146 (90.1%) patients with ccRCC. The level of HMGA2 was positively correlated with tumor size, lymph node metastasis, and Fuhrman Grade. A Kaplan–Meier analysis with log-rank test found that patients with high HMGA2 expression had a poor outcome and that patients with low HMGA2 expression had better survival. Cox regression analysis showed that HMGA2 expression could serve as an independent prognostic factor for ccRCC patients. The efficacy of the following prognostic models was improved when HMGA2 expression was added: tumor node metastasis stage, UCLA Integrated Scoring System, Mayo Clinic stage, size, grade, and necrosis score. In summary, this study showed that HMGA2 expression is an independent prognostic factor for OS in patients with ccRCC. HMGA2 was found to be a valuable biomarker for ccRCC progression.

show abstract

Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma

Abstract: Supplemental Digital Content is available in the text

Cited by 15 publications

References 26 publications

Searching for prognostic biomarkers for small renal masses in the urinary proteome

Searching for prognostic biomarkers for small renal masses in the urinary proteome

High expression of Aldolase A predicts poor survival in patients with clear-cell renal cell carcinoma

High expression of HMGA2 predicts poor survival in patients with clear cell renal cell carcinoma

Contact Info

Product

Resources

About